CAJ | 학술논문

目的：研究尼洛替尼对伊马替尼耐药慢性粒细胞白血病慢性期和加速期的临床疗效及不良反应。方法选择CML慢性期患者12例，加速期患者11例，采用尼洛替尼治疗后分别对疗效、LDH 及a-HBDH及安全性进行评估。结果12例慢性期患者6例获得CHR ，获得缓解的中位数时间为35 d；加速期11名患者中3例获得CHR ，获得缓解的中位数时间为41 d。慢性期患者治疗后LDH 及a-HBDH较治疗前显著下降（P＜0．05），加速期患者经治疗后LDH 及a-HBDH较治疗前显著下降（P＜0．05）。慢性期及加速期患者治疗期间血液系统不良反应主要体现在Ⅲ～Ⅳ级PL T、WBC、HB下降，非血液系统并发症主要体现在发热、皮疹及胃肠道反应。结论尼洛替尼治疗伊马替尼耐药CM L患者具有较好的缓解率且不良反应多可耐受。
목적：연구니락체니대이마체니내약만성립세포백혈병만성기화가속기적림상료효급불량반응。방법선택CML만성기환자12례，가속기환자11례，채용니락체니치료후분별대료효、LDH 급a-HBDH급안전성진행평고。결과12례만성기환자6례획득CHR ，획득완해적중위수시간위35 d；가속기11명환자중3례획득CHR ，획득완해적중위수시간위41 d。만성기환자치료후LDH 급a-HBDH교치료전현저하강（P＜0．05），가속기환자경치료후LDH 급a-HBDH교치료전현저하강（P＜0．05）。만성기급가속기환자치료기간혈액계통불량반응주요체현재Ⅲ～Ⅳ급PL T、WBC、HB하강，비혈액계통병발증주요체현재발열、피진급위장도반응。결론니락체니치료이마체니내약CM L환자구유교호적완해솔차불량반응다가내수。
Objective To study the clinical efficacy of nilotinib for chronic myeloid leukemia (CML) in chron-ic phase and accelerated phase .Methods A total of 12 patients with CML in chronic phase ,and 11 patients in ac-celerated phase were enrolled .Clinical efficacy ,LDH ,a-HBDH ,and safety was assessed after nilotinib therapy . Results Altogether 6 of the 12 chronic cases obtained CHR ,the median remission time being 35 d;3 of the 11 ca-ses in accelerated phase obtained CHR ,the median remission time being 41d .LDH and a-HBDH decreased signifi-cantly in all patients ( P<0 .05) .The adverse reactions were mainly PLT ,WBC and HB decline in grade Ⅲ-Ⅳ ,fe-ver ,rash and gastrointestinal reactions .Conclusion Imatinib-resistant CML patients showed effective response to nilotinib and could tolerate adverse reactions .